Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
A phase 1/2 trial of Fulvestrant, Letrozole in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
Overview
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07288359 by Novartis Pharmaceuticals, with 205 participants planned, started 2025-12-29 and due to reach its primary completion in 2031-05-09. Interventions recorded: GVV858, Fulvestrant, Letrozole. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Prostate cancer.
- TrialStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Shares Fulvestrant, Novartis.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Prostate cancer.
- TrialPF-07104091 as a Single Agent and in Combination Therapy
Shares Letrozole (and other aromatase inhibitors), Fulvestrant.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares Novartis, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Novartis, Prostate cancer.
- TrialA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Novartis, Prostate cancer.
- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares Novartis, Prostate cancer.